Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-target CAR-T (CD19/CD22, CD19/CD20) for Refractory/Relapsed B-cell Malignancies
NCT05388695Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Apr 2022
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22 CAR-T and CD19/CD20 CAR-T (Hebei Senlang) in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and 4 more, sponsored by Senlang Bio. Primary endpoint: Remission Rate at 3 months. Started Apr 2022; status: recruiting.
02
Drugs
CD19/CD22 CAR-TCD19/CD20 CAR-T (Hebei Senlang)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05388695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388695.